Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands.

Probert F.; Yeo T.; Zhou Y.; Sealey M.; Arora S.; Palace J.; Claridge TDW.; Hillenbrand R.; Oechtering J.; Kuhle J.; Leppert D.; Anthony DC.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands.

Probert F., Yeo T., Zhou Y., Sealey M., Arora S., Palace J., Claridge TDW., Hillenbrand R., Oechtering J., Kuhle J., Leppert D., Anthony DC.

[This corrects the article DOI: 10.3389/fimmu.2021.811351.].

Original publication

DOI

10.3389/fimmu.2022.1095038

Type

Journal article

Journal

Front Immunol

Publication Date

2022

Volume

Keywords

biomarker, diagnosis, metabolomics (OMICS), multiple sclerosis (MS), oligoclonal band, proteomics